Belgian start-up ActoGenix has raised $15 million in venture capital. The transaction was co-led by GIMV and Life Sciences Partners, with Biotech Fund Flanders also participating. ActoGeniX is a spin-off from the Flanders Interuniversity Institute of Biotechnology and Ghent University and was founded last June with seed capital from GIMV, VIB and individuals of the management team. It's a platform company, with drug research based on TopAct, a "delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals."
- see the release on the start-up